Microorganism-induced inflammation causing changes in different healthy tissues in human oral cavity
By analyzing the ratio of Bacteroidetes to Firmicutes in subgingival plaque samples, patients with chronic and advanced gingivitis can be distinguished, and appropriate oral care compositions can be selected according to the type. This solves the problems of prevention and treatment of gingivitis and periodontitis and improves treatment outcomes.
Patent Information
- Application Number
- CN202380021294.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-10
- Filing Date
- 2023-02-10
- Publication Date
- 2024-11-01
AI Technical Summary
Current technologies are insufficient to effectively differentiate and treat different types of gingivitis responders, making it difficult to prevent and treat the progression of gingivitis and periodontitis.
By analyzing the ratio of Bacteroidetes to Firmicutes (iFBR) in subgingival plaque samples, individuals were identified as responders to chronic or high-type gingivitis, and oral care compositions containing antimicrobial or anti-inflammatory ingredients were selected for treatment and prevention based on the type.
It enables personalized treatment and prevention for different gingivitis patients, improves the treatment effect of gingivitis and periodontitis, and reduces the chance of permanent damage.
Smart Images

Figure CN118891373A_ABST
Abstract
Description
[0001] References to Electronic Sequence Listings
[0002] The contents of the electronic Sequence Listing (Colgate 14220WO Sequence Listing.xml; size: 330,284 bytes; and creation date: February 10, 2023) are incorporated herein by reference in their entirety. Background Art
[0003] The gums, also known as gingiva, are part of the soft tissue lining of the oral cavity that surrounds the teeth and provides a seal around them. The gingival margin is the interface between the gingival sulcus epithelium and the oral epithelium. This interface exists at the most coronal point of the gums, also known as the crown of the marginal gingiva. The gingival crevice, also known as the gingival sulcus, is the space around the teeth between the wall of the unattached gingival tissue and the enamel and / or cementum of the teeth.
[0004] Healthy gums are firm and pale pink and fit tightly around the teeth. Typical signs and symptoms of gingivitis include red, swollen, tender gums that may bleed when you brush or floss. Oral infections are often associated with systemic health problems.
[0005] Gingivitis is an inflammation of the gums in the initial stages of gum disease. The direct cause of gingivitis is the unwanted microbial colonization of the teeth and gums by pathogenic bacteria. For example, pathogenic bacteria can produce toxins that can irritate the gum tissue, leading to gingivitis. In this early stage of gum disease, the damage can be reversed because the bone and connective tissue that hold the teeth in place have not yet been affected. However, untreated gingivitis can turn into advanced gum disease, periodontitis, and cause permanent damage to the teeth and jawbone.
[0006] Periodontitis, a chronic and irreversible form of periodontal disease, is an age-related inflammatory disease of the gums that is more common than cardiovascular disease and affects more than 795 million adults worldwide. Periodontitis is associated with dysbacterial dental plaques rich in Gram-negative bacteria such as Porphyromonas and Tannerella species. If left untreated, periodontitis can lead to imbalanced and chronic host immune responses, resulting in irreversible structural tissue damage and bone loss. Periodontal disease is even associated with other systemic diseases in humans, including arthritis, endocarditis, bacterial pneumonia, type 2 diabetes, and Alzheimer's. Gingivitis, a reversible and milder form of periodontal disease, is considered to be a precursor to the occurrence of most cases of periodontitis. However, the direct link between the pathogenesis leading to periodontitis from gingivitis remains unresolved. In addition, gingivitis and periodontitis usually occur in localized tooth sites, but susceptible individuals can have multiple lesions at different time periods and throughout their lifetime.
[0007] Gingivitis can be treated and resolved through good oral hygiene, such as longer and more frequent brushing, flossing, and the use of antibacterial mouthwashes. The earlier gingivitis is treated, the less chance of permanent damage. Therefore, methods of diagnosing gingivitis during its early stages allow treatment to be initiated before the condition progresses. Such methods can also be applied to monitor oral health and treatment over time.
[0008] A recent study using an experimental gingivitis (EG) model not only validated previously observed clinical changes in the host response to plaque-induced inflammation (high- and low-type responses) reported in the literature, but also identified a new clinical response type, the slow type (Bamashmous et al., 2021 Human Variation in Gingival Inflammation. Proc Natl Acad Sci USA Jul 6; 118 (27) e2012578118, which is incorporated herein by reference). These changes in gingival inflammation observed in humans are now considered to be clinical inflammatory response types (Inflammatory Response Type, IRT). Each of these phenotypes reveals well-defined clinical, microbial, and host mediator dynamics. Briefly, high IRT has a rapid plaque growth rate, a rapid increase in Gram-negative Bacteroidetes, high levels of host mediators, and high levels of inflammation; low IRT has a rapid plaque growth rate, a rapid increase in Gram-negative Bacteroidetes, low levels of host mediators, and low levels of clinical inflammation; and slow IRT has a delayed plaque growth rate, persistently high levels of Gram-positive Streptococci, and a delayed onset of clinical inflammation, but ultimately reaches high levels of inflammation - similar to high IRT.
[0009] Although the high level of inflammation in slow IRT is delayed in onset, both high IRT and slow IRT each exhibit high levels of inflammation. After reaching a high level of inflammation, high IRT and slow IRT can be distinguished from each other by measuring the IL-1β level in the gingival crevicular fluid sample from the individual at the site of gingivitis (gingivitis IL-1β level). In slow IRT individuals, the IL-1β level was not significantly changed compared to the IL-1β level in the gingival crevicular fluid measured before gingivitis (baseline or pre-gingivitis IL-1β level). In contrast, in high IRT individuals, the gingivitis IL-1β level was significantly increased compared to the pre-gingivitis IL-1β level.
[0010] Understanding the defenses and physical responses (e.g., the state and changes of the oral commensal bacterial flora) throughout the inflammatory process from initial plaque development to gingivitis and periodontal disease allows for the development and implementation of more effective preventive care and treatment and its products. Determining whether an individual is a slow-type IRT or a high-type IRT provides insights that can be used to provide effective treatment and preventive care for the individual. For individuals identified as slow-type IRT, it is preferred to use an oral care composition for treatment and preventive care, the oral care composition comprising an ingredient with antimicrobial activity and not containing an additional ingredient with anti-inflammatory activity. For individuals identified as high-type IRT, it is preferred to use an oral care composition for treatment and preventive care, the oral care composition comprising an ingredient with antimicrobial activity and an ingredient with anti-inflammatory activity. (U.S. Provisional Application 63 / 200,002, which is incorporated herein by reference in its entirety). Summary of the invention
[0011] A method for identifying an individual as a slow gingivitis responder or a high gingivitis responder based on the temporal changes in the bacterial composition of the oral microbiome in healthy tissue at a site away from the site of plaque-induced inflammation is provided. The method comprises the following steps: when the individual has been identified as not suffering from gingivitis, a subgingival plaque sample of pre-gingivitis origin is obtained from the individual. The bacterial composition of the subgingival plaque sample of pre-gingivitis origin is analyzed to determine the ratio of Bacteroidetes to Firmicutes (i.e., baseline iFBR) present in the subgingival plaque sample of pre-gingivitis origin. Two additional samples are obtained at different time points when plaque-induced inflammation associated with gingivitis occurs, and each additional sample is analyzed. An early distant healthy source of subgingival plaque sample is obtained from the individual, and the bacterial composition of the early distant healthy source of subgingival plaque sample is analyzed to determine the ratio of Bacteroidetes to Firmicutes (i.e., early iFBR) present in the subgingival plaque sample of early distant healthy origin. Obtain a late distant healthy source of subgingival plaque sample from the individual, and analyze the bacterial composition of the late distant healthy source of subgingival plaque sample to determine the ratio of Bacteroidetes to Firmicutes in the late distant healthy source of subgingival plaque sample (i.e., late iFBR). Compare baseline iFBR, early iFBR, and late iFBR. If the early iFBR is not significantly changed compared with the baseline iFBR, and the late iFBR is significantly changed compared with the baseline iFBR, the individual is identified as a slow gingivitis responder. If the early iFBR is significantly changed compared with the baseline iFBR, and the late iFBR is significantly changed compared with the baseline iFBR, the individual is identified as a high-type gingivitis responder.
[0012] In some embodiments, such a method of identifying an individual as a chronic gingivitis responder or a high gingivitis responder further comprises the steps of: examining the individual and determining that the individual does not suffer from gingivitis, and then obtaining a subgingival plaque sample of pre-gingivitis origin from the individual; and examining the individual and determining that the individual suffers from plaque-induced inflammation associated with gingivitis, and then obtaining an early distant healthy-derived subgingival plaque sample from the individual and then obtaining a late distant healthy-derived subgingival plaque sample from the individual.
[0013] Provided is a method for treating an individual who has been identified as suffering from gingivitis. Such a method can eliminate, improve symptoms and diseases or delay or prevent the progression of symptoms and diseases. The method includes identifying the individual as a chronic gingivitis responder or a high-type gingivitis responder. If the individual is identified as a chronic gingivitis responder, one or more oral care compositions are applied to the oral cavity of the individual, the oral care compositions comprising one or more ingredients with antimicrobial activity and not containing other ingredients with anti-inflammatory activity. If the individual is identified as a high-type gingivitis responder, one or more oral care compositions are applied to the oral cavity of the individual, the oral care compositions comprising one or more ingredients with antimicrobial activity and one or more ingredients with anti-inflammatory activity.
[0014] Provided is a method for preventing gingivitis and periodontal disease in an individual who has been identified as not suffering from gingivitis. Such a method can prevent symptoms and diseases, reduce the severity of symptoms and diseases, or delay the onset of symptoms and diseases. The method includes identifying the individual as a slow-type gingivitis responder or a high-type gingivitis responder. If the individual is identified as a slow-type gingivitis responder, one or more oral care compositions are applied to the oral cavity of the individual, the oral care compositions comprising one or more components with antimicrobial activity and not containing other components with anti-inflammatory activity. If the individual is identified as a high-type gingivitis responder, one or more oral care compositions are applied to the oral cavity of the individual, the oral care compositions comprising one or more components with antimicrobial activity and one or more components with anti-inflammatory activity.
[0015] In some embodiments of the methods of treating and preventing gingivitis, the one or more ingredients with antimicrobial activity used in such methods are selected from the group consisting of arginine, zinc phosphate, zinc oxide, zinc citrate, triclosan, digluconate, thymol, menthol, eucalyptol, methyl salicylate, saline, antibiotics, and fluoride.
[0016] In some embodiments of the methods of treating and preventing gingivitis, the one or more ingredients with anti-inflammatory activity used in such methods are selected from the group consisting of: chlorhexidine, DHA, and vitamin D.
[0017] In some embodiments of the methods of treating and preventing gingivitis, the one or more oral care compositions used in such methods are selected from the group consisting of toothpastes, mouth rinses, and mouthwashes. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1A Figures 1 to 1J contain data showing that control sites are not static and vary depending on inflammatory responder type. Figure 1A Shown are the Plaque Index (PI) stratified by Inflammatory Responder Type (IRT) during the induction phase (days 0 to 21) and respective controls. Figure 1B Linear regression of mean PI of test and control according to IRT during the induction phase is shown. Figure 1C Gingival Index (GI) stratified by IRT during the induction phase and respective controls are shown. The red dashed line indicates a GI value of 1.5, which indicates significant clinical inflammation in the gingival tissue. Figure 1D Linear regression of mean GI of test and control according to IRT during the induction phase is shown. Figure 1E Shown are Bleeding on Probing (BOP) stratified by IRT within the induction phase and respective controls. Figure 1F Linear regression of mean BOP for test and control according to IRT during the induction phase is shown. Figure 1G Shown are gingival crevicular fluid (GCF) volumes stratified by IRT during the induction phase and respective controls. Figure 1H Linear regression of mean GCF volume according to IRT test and control during the induction phase is shown. Fig. 1I Shown are the bacterial loads (16S copies) stratified by IRT within the induction phase and the respective controls. Figure 1J Linear regression of the average bacterial load according to IRT test and control during the induction phase is shown. Boxes represent data and median ± interquartile range; whiskers and outliers >1.5 IQR, below (above) the 25th (75th) percentile. Trend lines represent the loess regression mean at all time points. Statistical analysis was performed using the nonparametric Wilcoxon rank sum test adjusted for FDR. The significance level is indicated by an asterisk. Significance level: ns = not significant, *P < 0.05, **P ≤ 0.01 and ***P ≤ 0.001.
[0019] Figures 2A to 2DContains data showing that variations in subgingival plaque diversity were observed in healthy control sites and varied according to inflammatory responder type. Figure 2A Alpha diversity measured by observed Amplicon Sequence Variant (ASV) and Shannon Index is shown. Statistical significance was calculated by FDR-adjusted Wilcoxon rank sum test. Figure 2B Shown are the Bray-Curtis dissimilarity indexes for each inflammatory responder type (IRT) test during the induction phase (days 0 to 21) compared to day 0. Figure 2C The Bray-Curtis dissimilarity index for each IRT control during the induction phase (days 0 to 21) compared to day 0 is shown. Figure 2D β diversity calculated using weighted Unifrac distance and visualized by principal coordinate analysis is shown for each IRT of test and control. Marginal box plots represent PC1 and PC2 in the induction phase (days 0 to 21). Boxes represent data and median ± interquartile range; whisker lines and outliers>1.5IQR, below (above) the 25th (75th) percentile. Trend lines represent loess regression mean values at all time points. Dashed lines represent test sites and solid lines represent control sites. Statistical analysis was performed using the nonparametric Wilcoxon rank sum test adjusted by FDR. Significance levels are represented by asterisks. Significance levels: ns=not significant, *P<0.05, **P≤0.01, and ***P≤0.001.
[0020] Figures 3A to 3E Microbiome composition shifts within healthy control sites in a responder-dependent manner are shown. Figure 3A Relative abundance percentages of aggregated count data at the phylum level are shown for the 6 most abundant phyla. Dashed lines represent test sites and solid lines represent control sites according to clinical inflammatory responder types (IRT). Figure 3B A Z-score heat map of relative abundance using aggregated data at the genus level is shown. The heat map is then organized and grouped based on Gram stain names (including Gram-positive, Gram-negative) and by members of the Candidate Phyla Radiation (CPR). Key bacteria from each Gram classification are highlighted in red for comparison in different respondent test sites and control sites. Most are members of the Firmicutes and Bacteroidetes phyla or are associated with periodontal disease. Figures 3C to 3EThe relative abundance percentage of the aggregated data at the gate level grouped by IRT test site and control site during the induction phase is shown. The trend line represents the mean value among all time points. The whisker line represents the standard error.
[0021] Figure 4A and 4B The inverse Firmicutes / Bacteroidetes Ratio (iFBR) by inflammatory responder type is shown. The inverse Firmicutes / Bacteroidetes ratio (iFBR) was generated using the relative abundance data aggregated at the phylum level. The red dashed line in the figure represents 0 on the Log2 scale as a reference. Figure 4A Shown are iFBRs of test and control sites in different clinical inflammatory responder types (IRTs) and their respective controls. Figure 4B The iFBR of the test site and control site stratified by IRT is shown. In the figure, the red dotted line represents 0 on the Log2 scale as a reference. The box represents the data and the median ± interquartile range; the whisker line and the outliers are >1.5IQR, lower (higher) than the 25th (75th) percentile. The trend line represents the loess regression mean at all time points. The dotted line represents the test site and the solid line represents the control site. Statistical analysis was performed using the non-parametric Wilcoxon rank sum test adjusted by FDR. The significance level is indicated by an asterisk. Significance level: ns = not significant, *P < 0.05, **P ≤ 0.01 and ***P ≤ 0.001.
[0022] Figures 5A to 5D Amplicon sequence variants detected on the contralateral side between the test site and the control site are shown. The ASV level data were converted to a presence-absence matrix and plotted as a heat map to identify the contralateral detection between the test site and the control site during the induction period (days 0 to 21) according to the clinical inflammatory responder type (IRT). Gram-negative and candidate phylum radiation (CPR) genera enriched in the test site were selected for this analysis, resulting in a total of 3,509 ASVs. Red text (darker) indicates that the subject detected the ASV simultaneously between the test site and the control site. Blue text (lighter) indicates that the subject detected the ASV in the test site before any detection at the control site. Figure 5A It is shown that the subject's high-type IRT resulted in 29 (0.83%) ASVs detected on the contralateral side. 6 / 6 subjects had ASVs detected on the contralateral side. Figure 5B It is shown that the subjects' low-type IRT resulted in 15 (0.43%) ASVs detected on the contralateral side. 3 / 6 subjects had ASVs detected on the contralateral side. Figure 5CIt is shown that the subject's slow-type IRT produced 89 (2.5%) ASVs detected on the contralateral side. 8 / 9 subjects had contralaterally detected ASVs. Figure 5D is a table of the Gram-negative and CPR genera used in this analysis, the number of species detected within these genera, and the corresponding number of ASVs per genus.
[0023] Figures 6A to 6L It is shown that mature plaque in the test site induces changes in the host medium in the control site, which precedes the shift in the control site microbiome. Figures 6A to 6C Shown is a Z-score heat map of the log fold change of chemokines compared to baseline (Day 0) in different clinical inflammatory responder type (IRT) control sites. Key inflammatory mediators are highlighted in red text (lighter). Figures 6D to 6F IL-8 (left y-axis), IL-6 and TNF-a (right y-axis) in the IRT control site are shown. The red box (shaded) highlights the shift in host mediators in the control site. Figures 6G to 6I The relative abundance percentages of Firmicutes (left y-axis) and Bacteroidetes (right y-axis) obtained using aggregated data at the phylum level are shown. Trend lines represent mean values. Solid lines represent control sites and dashed lines represent test sites. Labels represent IRT test sites and control sites by phylum (i.e., HTF - high-type test Firmicutes, HCF - high-type control Firmicutes, HTB - high-type test Bacteroidetes, HCB - high-type control Bacteroidetes). Red boxes (shading) represent dysbiosis shifts in control sites. Figures 6J to 6L Graphical illustration of the temporal relationship of the microbiome and host media between the test and control sites during the induction phase (days 0 to 21). DETAILED DESCRIPTION
[0024] The terms "slow gingivitis responder," "slow responder," and "slow IRT" are used interchangeably.
[0025] The terms "high gingivitis responder," "high responder," and "high IRT" are used interchangeably.
[0026] The terms "low gingivitis responder," "low responder," and "low IRT" are used interchangeably.
[0027] The terms "non-gingivitis derived subgingival plaque sample" and "pre-gingivitis derived subgingival plaque sample" are used interchangeably and refer to a subgingival plaque sample obtained from an individual when the individual has been identified as not having gingivitis. The pre-gingivitis derived subgingival plaque sample provides a sample for identifying subgingival microbiome components and determining baseline levels of subgingival microbiome components, as well as determining the relative abundance of such components.
[0028] The term "early distant healthy source" is obtained from a healthy tissue site away from the site of gingivitis (i.e., the site of local plaque-induced inflammation) in an individual with local plaque-induced inflammation 21 to 28 days after professional dental cleaning or 7 to 14 days after the onset of local plaque-induced inflammation. An "early contralateral subgingival plaque sample" is an example of an early distant healthy source subgingival plaque sample.
[0029] "Early distant healthy source sample subgingival plaque sample" refers to a subgingival plaque sample obtained from a healthy tissue site away from the gingivitis site (i.e., the local plaque-induced inflammation site) in an individual with local plaque-induced inflammation 7 to 14 days after the onset of local plaque-induced inflammation, or if an induction program based on an experimental gingivitis model is used (which includes a 14-day pre-induction period, starting with daily cleaning and inspection, followed by a 21-day induction period, during which brushing is stopped), then a subgingival plaque sample is obtained 21 to 28 days after the start of the pre-induction phase (7 to 14 days after the start of the induction phase). "Early contralateral subgingival plaque sample" is an example of a late distant healthy source subgingival plaque sample.
[0030] "Late distant healthy source sample subgingival plaque sample" refers to a subgingival plaque sample obtained from a healthy tissue site away from the gingivitis site (i.e., the local plaque-induced inflammation site) in an individual with local plaque-induced inflammation 14 days after the onset of local plaque-induced inflammation, or if an induction program based on an experimental gingivitis model is used (which includes a 14-day pre-induction period, starting with daily cleaning and inspection, followed by a 21-day induction period, during which brushing is stopped), then a subgingival plaque sample is obtained 28 days after the start of the pre-induction phase (7 to 14 days after the start of the induction phase). "Late contralateral subgingival plaque sample" is an example of a late distant healthy source subgingival plaque sample.
[0031] The term "inverse Firmicutes / Bacteroidetes ratio (iFBR)" refers to the ratio of Bacteroidetes to Firmicutes present in subgingival plaque samples.
[0032] The terms "pre-gingivitis iFBR", "non-gingivitis iFBR" and "baseline iFBR" are used interchangeably and refer to the iFBR in a subgingival plaque sample of pre-gingivitis origin.
[0033] The term "early iFBR" is used to refer to iFBR in early distant healthy-derived subgingival plaque samples.
[0034] The term "late iFBR" is used to refer to iFBR in late distant healthy-derived subgingival plaque samples.
[0035] "Statistically elevated" and "significantly elevated" are used interchangeably and mean that one amount is higher than another amount and the difference is statistically significant.
[0036] "Unchanged" and "significantly unchanged" are used interchangeably and mean that one quantity is the same or nearly the same as another quantity, and the difference is not statistically significant.
[0037] "Oral care composition" refers to a composition that is delivered to the oral cavity surface. The composition can be a product that is not intended to be swallowed for the purpose of systemic administration of a particular therapeutic agent during the normal course of use, but is maintained in the oral cavity for a time sufficient to contact substantially all tooth surfaces and / or oral tissues for the purpose of oral activity. Some examples of such compositions include, but are not limited to, toothpaste or dentifrice, mouthwash or mouth rinse, topical oral gel, denture cleanser, and the like.
[0038] The stability of the host-microorganism interface is essential for the health in the human mucosal surface. Barrier immunity is not characterized by the absence of bacteria but by the regulated presence of bacteria under healthy immune surveillance. This is also referred to as the para-inflammatory state, and is necessary for tissue response to damage and restoration of homeostasis. This is particularly relevant to the mucosal surface, in which there is a continuous microbial attack on the host immune system. For example, in the oral mucosal surface, one of the main protective mechanisms of the tissue and therefore protects the host from undesirable microbial colonization is the continuous and highly coordinated transport of neutrophils from the local periodontal vasculature through healthy gingival tissue and into the gingival crevice. There, neutrophil surveillance is essential for maintaining the appropriate amount and composition of dental plaque, which is a highly evolved and organized bacterial community present on the tooth surface that actively contributes to normal periodontal tissue function.
[0039] Oral commensal bacteria actively participate in maintaining healthy neutrophil surveillance of gingival tissue and normal tissue and bone turnover processes. Disruption of this steady-state bacteria-host relationship occurs during experimental gingivitis studies, where it has been clearly established that increases in the number and type of oral commensal bacteria increase clinical indices of inflammation. Studies conducted in germ-free mice have shown that dental plaque is essential for normal neutrophil homing and also contributes to normal alveolar bone turnover processes. Therefore, appropriate neutrophil surveillance of dental plaque microbial biofilms leads to a process called "healthy homeostasis", which results in both colonization resistance (a microbial protection mechanism against infection) and maintenance of an appropriate microbial composition for normal periodontal bone and tissue function.
[0040] Model systems for studying the dynamics of host-microbe interactions during inflammatory events directly in humans in a well-controlled and reversible manner are limited. A unique advantage of conducting studies in the oral cavity is the availability of a model, experimental gingivitis (EG). Deliberate cessation of oral hygiene allows for high-resolution studies of the onset and occurrence of gingival inflammation, as well as understanding the changes in severity present in the population. The model allows normal dental plaque (abundant biofilm) to develop and mature along the gingival margin and in the periodontal pockets around human teeth, thereby leading to a relatively rapid host response as inflammation progresses to a clinically ill state. In addition, the model also allows for the study of local inflammatory effects in other healthy tissues at a distance in the human oral cavity.
[0041] In the experimental model of gingivitis induced by humans, plaque accumulation is a convenient and reproducible model that helps study the destruction of healthy tissue homeostasis. The human experimental gingivitis model provides a unique advantage of real-time monitoring of disease occurrence in order to study changes from the model, which has revealed rapid changes in clinical inflammation measurements parallel to the increase in microbial plaque biomass and composition changes during the occurrence of gingivitis. In addition, it has been reported that in human experimental gingivitis studies, the object-based susceptibility to plaque-induced gingival inflammation is an individual characteristic. It has been reported that individual responses to induced gingivitis can be divided into high-type and low-type clinical phenotypes, wherein the high-type response phenotype is related to a persistent high-responsiveness para-inflammatory state. Although almost everyone has recognized that there are differences in the clinical parameters of bacterial plaque accumulation in gingivitis studies since 1965, the factors that cause individual host responses to be significantly different have not yet been elucidated. In this report, three different clinical response groups were identified, and the granular parallel analysis of these groups revealed unique host and microbiome characteristics during the induction of inflammation.
[0042] Periodontal diseases, including periodontitis and gingivitis, are localized inflammatory diseases of the periodontium characterized by progressive destruction of the tissues supporting the teeth. However, the primary causes by which healthy teeth become susceptible or how the disease spreads beyond the local site of infection in a person remain less clear. The ability to identify biomarkers associated with the transition from health to disease, such as key bacteria, may provide additional insights into the mechanisms by which healthy tooth sites are susceptible to disease and / or disease progression. In addition, understanding the relationships associated with the different changes observed in the gingival inflammatory response, represented by an individual's clinical inflammatory responder type (IRT), may indicate an individual's risk of developing periodontal disease and / or progression to a more destructive and irreversible form.
[0043] Initially, two types of IRT were identified: high-type IRT, in which the host experiences extensive plaque-induced inflammation; and low-type IRT, in which the host does not experience a severe inflammatory response to plaque. The recent discovery of slow-type IRT, in which the host experiences extensive plaque-induced inflammation but such a response is delayed, provides new insights into maintaining good oral health and provides information on the most effective treatments to combat and prevent plaque-induced inflammation and gingivitis.
[0044] New methods for distinguishing high-type IRT from slow-type IRT are provided herein. Temporal changes in healthy control teeth during a recent experimental gingivitis study are described herein. In generally healthy young adults, microbially induced inflammation was produced in a test site in a well-controlled and reversible manner for a period of 21 days. By analyzing the subgingival microbiome using subgingival plaque, significant changes in the subgingival microbiome community were determined. Importantly, these changes were followed by similar trends observed in a distant test site located on the opposite side of the mouth. That is, the subgingival microbiome has undergone changes in healthy tissue at a site away from the site of plaque-induced inflammation. Methods are provided that require analysis of samples from healthy tissue at a site away from the site of plaque-induced inflammation and treatment of individuals based on the results of such analysis.
[0045] Taxonomic diversity from healthy control teeth changed over the 21-day period of induced inflammation. A slight increase in alpha diversity was observed in the high-IRT and slow-IRT groups, whereas it remained fairly stable in the low-IRT group ( Figure 2A In addition, similar changes in beta diversity and Bray-Curtis dissimilarity measures were observed between all IRT test sites and control sites ( Figures 2B to 2D ). Taxonomic analysis showed that most of the subgingival microbiome communities detected in this study were composed of two major phyla (Firmicutes and Bacteroidetes) ( Figure 3A and 3C In terms of oral health, Firmicutes are often associated with Gram-positive commensal bacteria, whereas Bacteroidetes are often associated with Gram-negative dysbiotic bacteria. This was confirmed by genus-level analysis, which examined the relative abundance of different genera stratified by Gram stain names within the test and control sites of all IRTs ( Figure 3B). However, in human gut microbiome studies, the opposite trend was observed, with Bacteroidetes associated with intestinal health and symbiosis, while Firmicutes were associated with dysbiosis and disease. In addition, in human gut microbiome studies, the use of the Firmicutes / Bacteroidetes ratio (FBR) as an indicator of intestinal microbiome status has been recognized. The inverse of the Firmicutes / Bacteroidetes ratio (iFBR) can be used as an indicator for assessing subgingival microbiome health / dysbiosis ( Figure 4A and 4B ). Application of the proposed iFBR stratified by IRT test and control sites revealed a temporal relationship between iFBR and the onset of clinically significant inflammation within both high-IRT and slow-IRT test sites. This trend was also observed in high-IRT and slow-IRT control sites, but with a delay ( Figure 4A and 4B Interestingly, although a shift toward a Bacteroidetes-dominated community was observed in the test site as early as day 4 in the low-type IRT, similar to the high-type IRT, unlike the other IRTs, the iFBR remained fairly stable in the distant control site during the induction phase (days 0 to 21).
[0046] Strain-level taxonomic data were also examined. A high-resolution approach was applied to investigate amplicon sequence variants (ASVs) representing strain-level diversity in 16S amplicon data to determine whether specific strains could drive these observations within and / or between individuals. Due to large differences in relative abundance between individuals, days, and sample sites, a presence / absence approach was applied for ASVs within the genus Bacteroidetes, in addition to Saccharibacteria, due to its strong association with oral inflammation. Figure 5D These taxa are summarized in . In brief, this analysis revealed high variability within and between individuals, but identified a large number of ASVs that were detected in the test sites before the control sites during the induction phase or in both the test and control sites ( Figures 5A to 5D ). Interestingly, many of these ASVs were detected between the test and control sites near the end of the induction phase. This analysis supports the idea that as plaque matures on teeth, eventually leading to dissemination, it is possible that the same ASVs may be detected in distant sites in the mouth. This is a possible mechanism by which other sites may become susceptible to periodontal disease or colonization by periodontal pathogens.
[0047] Temporal analysis of the subgingival microbiome data, specifically the relative abundance of the two most abundant phyla, Firmicutes and Bacteroidetes, supports the conclusion that normal plaque accumulation and maturation occurring within the test sites results in a shift in community composition toward dysbiosis. This suggests that subclinical changes in host media when coupled with mature biofilms elsewhere in the mouth can promote a subgingival environment more favorable to members of the phylum Bacteroidetes and may provide a mechanism by which local periodontal inflammation can cause distant healthy tooth sites to become susceptible. Furthermore, the analysis demonstrated that this relationship was modified by clinical inflammatory responder type (IRT) and suggests that different IRTs may have different levels of risk associated with periodontal disease and / or disease progression. Illustrative interpretations of these temporal dynamics are provided for each IRT ( Figures 6J to 6K ).
[0048] The changes observed in the healthy control sites were highly correlated with the changes we observed in the respective test sites. Due to the fact that these changes were shown to be IRT-dependent, and the fact that changes were shown between the test and control sites, it is unlikely that these changes are a normal colonization process after professional cleaning. Low-IRT, which is able to regulate its immune response and / or maintain periodontal homeostasis even in the presence of extensive plaque accumulation and community maturation, showed a lower tendency to affect distant healthy sites within the mouth. This may indicate that members of the low-IRT have a lower risk of infection of healthy tooth sites compared to high-IRT and slow-IRT, and that the low-IRT is a more clinically desirable phenotype. Low-IRT produces lower levels of inflammation compared to high-IRT and slow-IRT, although low-IRT has similar rapid plaque accumulation and a shift to a dysbiotic community composition as high-IRT, as shown in high-IRT and slow-IRT.
[0049] According to the method provided herein, a subgingival plaque sample from a pre-gingival source is obtained and used to determine a baseline iFBR. Subsequently, a subgingival plaque sample from an early distant healthy source and a subgingival plaque sample from a late distant healthy source are obtained and used to determine an early iFBR and a late iFBR, respectively. If the early iFBR is significantly changed relative to the baseline iFBR, the individual is identified as a high-type IRT and can be treated accordingly. If the early iFBR is not significantly changed relative to the baseline iFBR, but the late iFBR is significantly changed relative to the baseline iFBR, the individual is identified as a slow-type IRT and can be treated accordingly.
[0050] The method of collecting subgingival plaque samples is well known to those skilled in the art. Subgingival plaque samples from pre-gingival sources can be collected when individuals do not experience inflammation induced by local plaque. 7 to 14 days after the inflammation induced by local plaque occurs, subgingival plaque samples from early distant healthy sources are obtained from healthy tissue sites rather than inflammation sites. After 14 days after the inflammation induced by local plaque occurs, subgingival plaque samples from late distant healthy sources are obtained from healthy tissue sites rather than inflammation sites. In some embodiments, plaque-induced inflammation associated with gingivitis can be intentionally induced as part of a program to determine the type of inflammatory response of an individual. After cleaning and inspection to determine that gingivitis does not exist, subgingival plaque samples from pre-gingival sources of gingivitis can be collected and used to establish a baseline iFBR. In some embodiments, the baseline iFBR is determined using samples collected on day 0. Cleaning and inspection start the 14-day pre-induction period of the hygienic phase (day -14 to day 0). On day 0, the individual begins a 21-day induction period, during which the individual avoids brushing the entire oral cavity or one side of the oral cavity as in the experimental gingivitis model, during which plaque-induced inflammation associated with gingivitis occurs. On days 7 to 14 of the induction phase (7 to 14 days after stopping brushing; 21 to 28 days after cleaning and baseline sample collection; early distant healthy-derived subgingival plaque samples), subgingival plaque samples can be collected at one or more healthy tissue sites (e.g., healthy tissue sites on the opposite side of the inflammation site) away from the site where inflammation occurs, for analysis and establishment of early iFBR. After 14 days of the induction phase (after 14 days after stopping brushing; after 28 days after cleaning and baseline sample collection; late distant healthy-derived subgingival plaque samples), subgingival plaque samples can be collected at one or more healthy tissue sites (e.g., healthy tissue sites on the opposite side of the inflammation site) away from the site where inflammation occurs, for analysis and establishment of late iFBR.
[0051] Methods for collecting subgingival plaque samples are well known. In some embodiments, a sterile paper point (STER-I-CELL paper point, size M; Coltene, Whaledent, Cuyahoga Falls, OH, USA) is inserted into the gingival sulcus of six maxillary teeth for 30 seconds to collect samples. Multiple samples can be collected and combined. DNA can be extracted using a commercially available kit (e.g., QIAamp DNA microbiome kit; Qiagen, Germany).
[0052] DNA extraction methods can include positive and negative controls. Quantitative real-time PCR is performed to determine the total bacterial load in each sequencing sample. A qPCR standard curve can be generated using known genomic DNA.
[0053] The merged reads were analyzed using the Quantitative Insights into MicrobialEcology (QIIME2) pipeline workflow to generate amplicon sequence variants (ASVs). The Human Oral Microbiome Database (HOMD (Human Oral Microbiome Database) 16S rRNA RefSeq v.15.1) was used for taxonomic assignment to classify ASVs.
[0054] Commercially available purification kits can be used for sample purification and determination of DNA concentration to further purify and increase DNA yield. Commercially available kits can also be used to determine DNA concentration.
[0055] Comprehensive microbial profiling of subgingival plaque samples can be performed by high-throughput sequencing of the 16S rRNA gene following the standard Illumina Miseq system protocol. Briefly, DNA amplification was performed using primers with overhanging Illumina flowcell adapter sequences targeting the hypervariable (V3 and V4) regions of the bacterial 16s rRNA gene.
[0056] Commercially available PCR kits can be used to amplify samples. Magnetic beads can be used to purify and index the amplicons, and the indexed PCR amplicons can be further purified with magnetic beads. Commercially available normalization kits can be used for library normalization prior to sequencing.
[0057] Analysis of sequencing data can be performed using automation.Taxonomic assignments to classify amplicon sequence variants (ASVs) can be performed using a database containing primarily full-length 16S rRNA gene reference sequences.
[0058] Community richness was measured by: species observed in the sample: total counts of unique ASVs; and the nonparametric richness estimate Chao1, which takes into account the number of singletons and doubletons. Total community diversity (richness and evenness) can be measured by: Simpson's inverse diversity index, Shannon index, and Faith phylogenetic diversity (PD), which uses phylogenetic distance to calculate alpha diversity.
[0059] Beta diversity, i.e., diversity between samples, was determined using a phylogenetic Unifrac distance that measured unweighted (presence / absence) and a weighted (relative abundance) Bray-Curtis dissimilarity matrix based on ASVs, which took into account both the presence / absence and abundance of unique ASVs. Beta diversity metrics were calculated using the coordinate function in "phyloseq", and visualized using a non-metric multidimensional scaling (NMDS) plot using the plot oridination function in "phyloseq". Quantitative real-time PCR can be performed to determine the total bacterial load in each sequencing sample.
[0060] In some embodiments, components present in the microbiome can be identified, and their relative abundance is determined by conventional methods. In some embodiments, genomic DNA is extracted from subgingival plaque using QIAamp DNA Mini kit (QIAGEN Sciences, USA). In some embodiments, additional lysozyme treatment (3 mg / ml, 1.5 hours) is performed for bacterial cell lysis. DNA concentration and purity are measured, for example, with NanoDrop ND-1000 spectrophotometer (ThermoFisher Scientific, USA) and monitored on 1% agarose gel. 16S rRNA gene sequencing is used to analyze the microbiome. Illumina Hiseq (Novogene Bioinformatics Technology Co., Ltd.) can be used to evaluate bacterial composition and diversity with 16S rRNA V4 gene. The polymerase chain reaction (polymerase chain reaction, PCR) amplification in the V4 region of bacterial 16S rRNA gene can be performed using specific primers (e.g., 515F and 806R). The sequencing library can be generated using the TruSeqTM DNA PCR-Free Sample Preparation Kit (Illumina, USA) according to the manufacturer's recommendations. The library can be sequenced on an Illumina HiSeq 2,500 and 250 bp paired-end reads are generated, and the raw reads are deposited in the NCBI Sequence Read Archive (SRA) database.
[0061] In some embodiments, methods of treating an individual who has been identified as having gingivitis are provided. The treatment method may include identifying the individual as a slow responder or a high responder, and then treating the individual based on whether they are a slow responder or a high responder.
[0062] An individual identified as having gingivitis may be treated to resolve the gingivitis based on whether the individual is a slow responder or a high responder. A method of treating an individual having gingivitis comprises identifying an individual having gingivitis as a slow responder or a high responder by the above method, and then treating such an individual based on whether the individual is identified as a slow responder or a high responder.
[0063] In some embodiments, an individual suffering from gingivitis and identified as a slow responder can be treated by applying an oral care composition to the individual's oral cavity, the oral care composition being an antibacterial mouth rinse. In some embodiments, an individual suffering from gingivitis and identified as a slow responder can be treated by applying an oral care composition to the individual's oral cavity, the oral care composition comprising one or more ingredients selected from the following: arginine, zinc phosphate, zinc oxide, zinc citrate, triclosan, digluconate, thymol, menthol, eucalyptol, methyl salicylate, saline, antibiotics, and fluoride. In some embodiments, the individual does not suffer from gingivitis but has been identified as a slow responder. Slow responders can be treated prophylactically by applying an oral care composition to the individual's oral cavity, the oral care composition comprising one or more ingredients selected from the following: arginine, zinc phosphate, zinc oxide, zinc citrate, triclosan, digluconate, thymol, menthol, eucalyptol, methyl salicylate, saline, antibiotics, and fluoride.
[0064] In some embodiments, an individual who suffers from gingivitis and has been identified as a high responder can be treated by applying to the individual's oral cavity an oral care composition comprising an antibacterial component, such as one or more ingredients selected from the group consisting of arginine, zinc phosphate, zinc oxide, zinc citrate, triclosan, digluconate, thymol, menthol, eucalyptol, methyl salicylate, saline, antibiotics, and fluoride, and further comprising an anti-inflammatory component, such as one or more ingredients selected from the group consisting of chlorhexidine, DHA, and vitamin D. In each case, the multiple components may be included in a single oral care composition or in two or more separate oral care compositions. In some embodiments, the individual does not suffer from gingivitis but has been identified as a high responder. High responders can be treated prophylactically by applying to the individual's oral cavity an oral care composition comprising a digluconate antibacterial component, such as one or more ingredients selected from the group consisting of arginine, zinc phosphate, zinc oxide, zinc citrate, triclosan, digluconate, thymol, menthol, eucalyptol, methyl salicylate, saline, antibiotics, and fluoride, and an anti-inflammatory component, such as one or more ingredients selected from the group consisting of chlorhexidine, DHA, and vitamin D.
[0065] Example
[0066] Such a study was designed: it aims to characterize the changes observed in the remote healthy control site located on the contralateral side of the maxilla over a period of 21 days, which are associated with the gingival inflammation induced by normal plaque accumulation and maturation in the test site. Significant changes in the human oral cavity were observed, which were directly caused by the induced inflammation occurring in the remote site in the oral cavity. It is worth noting that in healthy controls, the increase in proinflammatory host mediators (IL-8, IL-6, IL1-b and TNF-a) associated with periodontal inflammation and the dysbiosis ecological shift in the subgingival microbiome (represented by the inverse of the ratio of Firmicutes / Bacteroidetes (iFBR) proposed) were not present in any significant clinically observed inflammation in these remote healthy sites. This effect is affected by the individual inflammatory responder type (IRT). The microbial shift in the healthy site is most obvious in high-type IRT and slow-type IRT, where high-type IRT has a rapid contralateral effect, while slow-type IRT has a delayed contralateral effect. Interestingly, low-type IRT had a reduced contralateral effect, which was able to modulate its immune response within the test site and did not achieve the same elevated inflammation levels as high-type IRT and slow-type IRT. These findings enhance our understanding of changes in specific host inflammatory response types to local plaque-induced inflammation and subsequent effects in distant healthy tissues that affect both host mediator characteristics and microbial community composition. Such changes may represent a precursor event that leads to an increased risk of gingival inflammation in distant otherwise healthy sites in the human oral cavity.
[0067] method
[0068] The study consisted of the following phases: 1) a hygiene phase, which lasted two weeks prior to baseline (days −14 to 0), 2) a gingivitis induction phase, which lasted three weeks (days 0 to 21), and 3) a resolution phase, which lasted two weeks (days 21 to 35) ( Figure 1A During the experimental induction phase, subjects were given a custom-made intraoral stent that prevented oral hygiene at the experimental site. The fidelity of the intervention was monitored at each time point throughout the experiment by clinically assessing the plaque index.
[0069] On Day -14, a comprehensive clinical evaluation and biospecimen collection were performed after obtaining informed consent and verifying inclusion / exclusion criteria. After obtaining a maxillary impression for bracket fabrication, full-mouth prophylaxis was implemented and comprehensive oral hygiene instructions were given. Participants returned 7 to 14 days after this initial visit and their baseline (Day 0) measurements, and biospecimen collection was obtained. Participants were given acrylic brackets during regular toothbrushing with detailed instructions for use, with the goal of preventing accidental brushing of the experimental site. Participants were instructed not to brush their teeth on the test side (under the provided bracket) and not to employ any other oral hygiene measures, such as flossing or interdental aids. For the control side and the rest of the mouth, participants were instructed to use the provided toothbrush ( Gum Comfort Toothbrush), Toothpaste ( Cavity Protection Great Regular Flavor Fluoride Toothpaste) and dental floss (Oral BGlide), and avoided the use of mouthwash and chewing gum throughout the study. Participants returned on Day 4 and weekly thereafter for clinical assessments and sample collection each time using the same criteria as at the baseline visit. The "no brushing" portion of the experiment lasted for 21 days to allow all participants to develop gingivitis. After the samples and clinical assessments were obtained on Day 21, additional comprehensive prophylaxis was applied. Starting on the same day, participants again received detailed instructions on oral hygiene methods, using the provided electric toothbrush (Philips Sonicare electric toothbrush), toothpaste ( Cavity Protection GreatRegular Flavor Fluoride Toothpaste) and dental floss (Oral B Glide) were continued twice daily during the regression phase. Gingival assessment and biospecimen collection continued weekly during the reversal phase. Medical history and exclusion criteria were reviewed at each study visit.
[0070] A bracket was made that contained only the occlusal surfaces of the teeth under study and eliminated contact with the cervical margin of each tooth, thereby reducing the risk of plaque disturbance during bracket insertion or removal. The bracket was constructed of a 3 mm thick plastic mouthguard material. The elimination of cervical contact was achieved by blocking the peri-gingival margin and proximal surfaces using spacers made of 1 mm thick mouthguard material. The bracket was trimmed vertically on the buccal side to a length just shorter than the vestibule and extended 4 to 5 mm on the palatal side. In addition, the bracket was trimmed mesially to the middle of the canine and distally to the middle of the second molar.
[0071] At each study visit, subgingival plaque samples were collected from both the control and test sides. A sterile paper tip (STER-I-CELL paper tip, size M; Coltene, Whaledent, Cuyahoga Falls, OH, USA) was inserted into the gingival sulcus of six maxillary teeth for 30 seconds. At each study visit, a total of six samples / study sides were collected and merged, and the samples were transferred to the laboratory on ice and then frozen at -80 ° C until further analysis. DNA was extracted using a commercially available kit (QIAamp DNA microbiome kit; Qiagen, Germany) according to the manufacturer's protocol using both mechanical and chemical cell lysis. Sample purification and quality control were performed as described above.
[0072] For DNA extraction, negative controls were implemented by performing the DNA extraction protocol with kit reagents alone or with the aid of sterile paper tips in the case of plaque-free samples to assess contamination. In addition, positive controls using known bacterial cultures were included to validate the efficiency of the technique. Quantitative real-time PCR was performed to determine the total bacterial load in each sequencing sample. qPCR standard curves were generated from serially diluted Fusobacterium nucleatum ATCC 10953 genomic DNA.
[0073] The merged 300 bp paired-end reads (average length of 450 bp) were analyzed using the Quantitative Investigation of Microbial Ecology QIIME2, following the Distinguishing Amplicon Denoising Algorithm 2 (DADA2) pipeline workflow to generate amplicon sequence variants (ASVs). Taxonomic assignments were performed using the Human Oral Microbiome Database (HOMD 16S rRNA RefSeq v.15.1) to classify ASVs. The data were integrated into a single object using the “phyloseq” R package and further analyzed.
[0074] Sample purification was performed using a purification kit (DNA Clean & Concentrator-5 kit; Zymo Research, Orange, CA, USA) to further purify and improve DNA yield. After DNA extraction and purification, a fluorometer (Qubit 2.0; Life Technologies, Carlsbad, CA, USA) was used to determine the DNA concentration in the sample by fluorescence (Quant-iT dsDNA HS assay kit; Invitrogen, Carlsbad, CA, USA). The samples were stored at -20°C until ready for sequencing.
[0075] Comprehensive microbial profiling of subgingival plaque samples was performed by high-throughput sequencing of the 16S rRNA gene following standard Illumina Miseq system protocols. Briefly, DNA amplification was performed using primers with overhanging Illumina flow cell adapter sequences targeting the hypervariable (V3 and V4) regions of the bacterial 16s rRNA gene. The primers used were as follows:
[0076] SEQ ID NO: 1 is the 16S amplicon PCR forward primer: 5′-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG-3′.
[0077] SEQ ID NO: 2 is the 16S amplicon PCR reverse primer: 5′-TCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC-3′).
[0078] Samples were amplified in singleton in a 96-well plate format. Each reaction was performed using a PCR kit (KAPA HiFiHotStart ReadyMix; KAPA Biosystems, Boston, MA, USA) in a total volume of 25 μl, which contained the following reagents: 2.5 μl of extracted DNA, 5 μl of both forward and reverse primers (1 μM each) and 12.5 μl 2×KAPA HiFiHotStart ReadyMix. Amplicon PCR was performed on a thermal cycler (C1000 Touch temperature cycler; BioRad, Hercules, CA, USA) using the following program: a denaturation phase at 95°C for 3 minutes, followed by 35 to 40 cycles of denaturation at 95°C for 30 seconds, annealing at 55°C for 30 seconds, and extension at 72°C for 30 seconds, and then a final extension phase at 72°C for 5 minutes. The amplicon size generated by the first PCR was about 460 bp, which was visually verified by running each reaction on 1% agarose gel electrophoresis at 100 V for 30 minutes. The amplicon was then purified using magnetic beads (Agencourt AMPure XP beads; Agencourt Bioscience Corporation, Beckman Coulter Inc., Beverly, MA, USA) and indexed (Nextera XT v2 indexing kit, set A, B and D; Illumina, San Diego, CA, USA). The index PCR conditions included a denaturation phase at 95°C for 3 minutes, followed by 8 cycles of denaturation at 95°C for 30 seconds, annealing at 55°C for 30 seconds and extension at 72°C for 30 seconds, and then a final extension phase at 72°C for 5 minutes. The indexed PCR amplicons were further purified with magnetic beads (Agencourt AMPure XP beads; Agencourt Bioscience Corporation, BeckmanCoulter Inc., Beverly, MA, USA), and the quality and size of the library were checked (high sensitivity D1000 reagent and Agilent 4200 TapeStation system; Agilent Technologies, Santa Clara, CA, USA). Subsequently, the library was normalized using a normalization kit (SequalPrep Normalization Plate Kit; ThermoFisher Scientific, Waltham, MA, USA). The normalized libraries were combined and denatured with sodium hydroxide (NaOH) (Fisher Scientific, Pittsburgh, PA, USA).At least 20% control DNA (PhiX Control v3 library, Illumina, San Diego, CA, USA) was added to the denatured library (20 pM) and then loaded into the sequencer. Paired-end sequencing was performed on a sequencing platform (MiSeq system, Illumina, San Diego, CA, USA) using a 2×300 cycle sequencing kit (MiSeq Reagent Kits v3, Illumina, San Diego, CA, USA).
[0079] Using the Microbial Ecology Quantitative Study QIIME2, the sequencing data was analyzed according to the Distinguishing Amplicon Denoising Algorithm 2 (DADA2) pipeline workflow. A total of 16M paired-end reads were generated, with an average read of 41,017 for each sample. The original paired-end reads were imported into QIIME2 (v.2018.2), and after demultiplexing by Casava (v.1.8), both the forward and reverse reads were trimmed by 10bp and truncated to 290bp and 200bp, respectively. After quality filtering and denoising the sequence and removing chimeras and singletons, a total of 2,219,156 high-quality merged reads with an average length of 452bp were used for downstream analysis. The latest human oral microbiome database (HOMD 16SrRNA RefSeq v.15.1) was used for classification assignment to classify amplicon sequence variants (ASVs), which is a highly selected database that is specific to the human oral cavity and mainly contains full-length 16S rRNA gene reference sequences. The samples were then filtered for classification contaminants based on negative controls (kit reagents only or kit reagents with the aid of sterile paper tips). Phylogenetic trees were constructed using FastTree. Unrefined data was used for downstream analysis. Sequencing data were integrated into a single object using the "phyloseq" R package, and all subsequent data analysis and graphs were generated in R Studio. Richness and pd were estimated by functions in the "phyloseq" and "picante" R packages, and alpha diversity in sample diversity was calculated using both richness and uniformity metrics. Richness estimation graphs were generated using the "ggplot2" package in R.
[0080] Community richness was measured by: species observed in the sample: total counts of unique ASVs; and the nonparametric richness estimate Chao1, which takes into account the number of singletons and doubletons. Total community diversity (richness and evenness) was measured by: inverse Simpson diversity index, Shannon index, and Faith phylogenetic diversity (PD), which uses phylogenetic distance to calculate alpha diversity.
[0081] Beta diversity, i.e., diversity between samples, was determined using phylogeny-based Unifrac distances, which measured phylogenetic distances between both unweighted (presence\absence) and weighted (relative abundance) samples, and an ASV-based Bray-Curtis dissimilarity matrix, which takes into account both presence / absence and abundance of unique ASVs. Beta diversity metrics were calculated using the coordinate function in "phyloseq" and visualized using non-metric multidimensional scaling (NMDS) plots using the plot oridination function in "phyloseq".
[0082] Quantitative real-time PCR was performed to determine the total bacterial load in each sequencing sample. Samples were analyzed in duplicate in a 96-well plate using a thermal cycler (CFX96 Real-Time System C1000 Thermal Cycler; BioRad Laboratories, Hercules, CA, USA). qPCR standard curves were generated from serial dilutions of Fusobacterium nucleatum ATCC 10953 genomic DNA ranging from 108 to 101 16s copies. Each reaction was performed in a total volume of 20 μl, which consisted of 2 μl DNA or added to 10 μl master mix (TaqMan TM Fast Advanced Master Mix (TaqMan TM The primer set specifically targeting the 16S rRNA gene was added at a final concentration of 900 nM.
[0083] SEQ ID NO: 3 is the forward primer used: 5'-TCCTACGGGAGGCAGCAGT-3'.
[0084] SEQ ID NO: 4 is the reverse primer used: 5'-GGACTACCAGGGTATCTAATCCTGTT-3'.
[0085] In addition, 200 nM of TaqMan probe was used. The TaqMan probe used consists of a fluorophore 6-carboxyfluorescein (FAM) covalently linked to the 5' end of the oligonucleotide probe having SEQ ID NO: 5 and a quencher tetramethylrhodamine (TAMRA) covalently linked to the 3' end. Therefore, the TaqMan probe has the structure (6-FAM)-(SEQ ID NO: 5)--(TAMRA). SEQ ID NO: 5 is an oligonucleotide of the TaqMan probe and has the sequence: 5'-CGTATTACCGCGGCTGCTGGCAC-3' (Sigma Aldrich, St Louis, MO, USA).
[0086] Nuclease-free water was added to bring the total reaction volume to 20 μl. Negative control samples were included in the run using nuclease-free water to ensure that no contamination occurred. The qPCR run consisted of the following amplification conditions: 50°C for 2 minutes (UNG incubation); 95°C for 20 seconds (polymerase activation); 40 cycles of 95°C for 3 seconds (denaturation) and 60°C for 30 seconds (annealing / extension). Subgingival bacterial load was calculated using regression mode (Cq determination mode) (BioRad CFX software V3.1; BioRad Laboratories, Hercules, CA, USA).
[0087] Because the induction and resolution of experimental bacteria-driven gingivitis resulted in an inverted U-shaped distribution of in vivo bacterial biomass (total bacterial 16S rRNA gene copy number), a quadratic regression model was used to better investigate the temporal changes in subgingival microbial composition and load. A second-order polynomial was used to implement the quadratic regression model in R, and the direction of the coefficient and p-value representing the quadratic term are reported.
[0088] The longitudinal changes in subgingival microbial composition and load during gingivitis induction were statistically analyzed using R software (v.3.5.1). Subgingival bacterial load data were log-transformed (base 10) before analysis. In a similar manner to the clinical data, linear mixed models were used to determine differences in subgingival microbial load and alpha diversity index between the test and control sides and between different responder groups.
[0089] Differences in microbial community composition over time between the test and control sides or between different responder groups were evaluated by permutational analysis of variance (PERMANOVA) on the calculated beta diversity matrix (Bray-Curtis and UniFrac distances) using the function adonis in the “vegan” package (v.2.5-4). Multiple comparisons between groups were performed by pairwise PERMANOVA using the function pair.perm.manova in the “RVAideMemoire” package adjusted for false discovery rate (FDR).
[0090] To determine statistically significant differences in clustered and normalized amplicon sequence variants (ASVs) between sample and responder groups, we applied unpaired nonparametric Kruskal Wallis one-way analysis of variance (anova) and nonparametric Wilcoxon-Mann-Whitney test—both with 95% confidence intervals (α=0.05) and with false discovery rate (FDR) adjustment—using centered log ratio (CLR) transformed data generated by the “microbiome” R package through the “rsatix” and “ggpubr” R packages.
[0091] For statistical analysis at the genus level, the normalized abundance of amplicon sequence variants (ASVs) was clustered to the genus level using a new average clustering strategy from day -14 to day 35 according to the following responder groups: high, low, and slow (n = 293 samples from 21 subjects). This average clustering method using ASV abundance aims to provide better resolution of aggregate abundance data at different taxonomic levels by considering the number of unique ASVs at each taxonomic level, in an attempt to reduce the signal that can lead to overestimation of taxa in samples, individuals, and / or groups.
[0092] result
[0093] Control sites are not static and vary according to inflammatory responder type
[0094] At the time of inclusion (Day -14), all study participants received professional cleanings designed to normalize oral health status in individuals. At baseline (Day 0), study subjects refrained from brushing their teeth on the test sites protected by a personalized plastic stint in their mouths, while control sites maintained routine oral hygiene with fluoride toothpaste for a period of 21 days. During the induction period (Days 0 to 21), the plaque index (PI) remained fairly stable in the control sites ( Figure 1ADuring the induction period, no clinical inflammation as indicated by gingival index (GI) and bleeding on probing (BOP) was observed at control sites in these generally healthy individuals ( Figure 1C to IF). However, in the gingival crevicular fluid (GCF) volume ( Figure 1G and 1H ) and bacterial load ( Fig. 1I and 1J ) Changes were observed in the control sites, but the magnitude of change was lower compared to the test sites. The bacterial load, which represents the number of 16S rRNA gene copies within the sample, increased in all inflammatory responder types (IRTs), but had a stable PI. Although microbial diversity and host media changes at the test sites have been previously reported (Bamashmous et al., 2021 supra), these observations warrant further study of microbial diversity and host media changes within these distant control sites.
[0095] Variations in subgingival plaque diversity were observed in healthy control sites and varied according to inflammatory responder type
[0096] For each inflammatory responder type (IRT), the microbial diversity of the test and control sites was assessed. The microbial diversity was assessed by observed amplicon sequence variants (ASVs) and the Shannon index ( Figure 2A ) demonstrated changes in control and test sides between IRTs. The Bray-Curtis dissimilarity index was also assessed for each IRT relative to baseline (day 0) and highlighted detectable increases in dissimilarity across all IRT test and control sites during the induction period ( Figure 2B and 2C β diversity was compared using principal coordinates analysis with weighted Unifrac distances ( Figure 2D ). The test side showed a clear shift in beta diversity between days 0 and 21. On the control side, the high-IRT and slow-IRT showed similar shifts, but more gradual than the test side, while the low-IRT control showed a relatively stable community.
[0097] Microbiome composition varies within healthy control sites in a responder-dependent manner
[0098] Subgingival plaque samples were examined at the phylum and genus level and provided insights into the variation in microbial diversity. Relative abundance at the phylum level was assessed by inflammatory responder type (IRT) and their respective controls. The top six major phyla were assigned using the number and relative abundance of amplicon sequence variants (ASVs) within the phylum as a measure of within-sample dominance. The average relative abundance of these phyla was Figure 3AHighlighted in . Several trends were evident. There were clear shifts under the phylum, particularly an increase in the Gram-negative associated Bacteroidetes and a decrease in the Gram-positive associated Firmicutes. There were differences between the test and control sides and between the three IRTs. As seen by the results for the Actinobacteria, the shift in the control was not simply a version of the test side; rather, Actinobacteria showed an increase in relative abundance in the control during the induction phase (days 0 to 21), but decreased levels on the test side during the same time period. The changes on the control side also seem unlikely to be normal maturation of the subgingival biofilm community after deep cleaning, as some changes were different between the IRTs.
[0099] When examining the data at the genus level, z-score heatmaps of relative abundance were stratified by Gram stain name (positive and negative) and by membership of candidate phyla radiation (CPR) ( Figure 3B ). During the maturation of the community on the test side, a large number of genera were enriched, producing the induced inflammation. Many of these genera were also enriched in the control site, in particular: Selenomonas, Aggregatibacter, Porphyromonas, Treponema, Tannerella, Alloprevotella, Prevotella, and genera from the Monosaccharidae phylum. However, the majority of these enriched members belonged to the Firmicutes and Bacteroidetes phyla, which requires further investigation.
[0100] During the induction phase of each IRT, dynamics of Firmicutes and Bacteroidetes were observed in both test and control sites ( Figure 3C During the induction period, Firmicutes decreased in all IRT test and control sites, while Bacteroidetes increased in all IRT test and control sites ( Figure 3C ). This suggests that the inverse of the Firmicutes / Bacteroidetes ratio (iFBR) can be used as a metric to assess subgingival plaque dysbiosis, with an increase in Bacteroidetes associated with disease and an increase in Firmicutes associated with steady-state health. We plotted the iFBR for test and control sites within each IRT ( Figure 4A and Figure 4B). On day 4 of the induction phase, a shift from a microbiome dominated by Firmicutes to a Bacteroidetes phylum occurred in the test sites of both high and low IRT. However, the shift in the test sites in the slow IRT was delayed until day 7, which is characteristic of this responder phenotype (Bamashmous et al., 2021). After the shift in the test sites, iFBR also shifted in the control sites. For high IRT, the shift in the control sites was delayed until day 7, and for low and slow IRT, it was delayed until day 14. However, the changes in iFBR observed in the control sites during the induction phase were statistically significant only for high and slow IRT.
[0101] Detection of amplicon sequence variants on opposite sides between the test site and the control site
[0102] Amplicon sequence variants (ASVs) represent strain-level diversity of 16S rDNA gene sequencing data (21). During the induction of inflammation, a total of 3,509 ASVs from enriched genera identified at the test sites were examined at the strain level for contralateral detection, including: Lunar spp. (19 species, 433 ASVs), Aggregatibacter (7 species, 155 ASVs), Porphyromonas (10 species, 414 ASVs), Treponema (23 species, 233 ASVs), Tannerella (3 species, 118 ASVs), Pseudoprevotella (7 species, 285 ASVs), Prevotella (38 species, 1602 ASVs), and Monosaccharobacteria (8 species, 269 ASVs) ( Figure 5D Using the presence / absence heatmap of 3,509 ASVs of the enriched genera, 29 ASVs were detected on the contralateral side in the high-type IRT (0.83%), of which 6 / 6 subjects had an ASV detected on the contralateral side ( Figure 5A ). 15 ASVs were detected on the contralateral side in 3 / 6 low-type IRT subjects (0.43%) ( Figure 5B ). 89 ASVs were detected on the contralateral side in 8 / 9 subjects in slow-type IRT (2.5%) ( Figure 5C ). Although all IRTs showed contralateral ASV detection, high-type IRT and slow-type IRT showed higher ratios compared with low-type IRT. This is consistent with the fact that for PI and bacterial load, higher levels were observed in high-type IRT and slow-type IRT ( Figure 1A and 1I ), as well as previous characterization of different clinical inflammatory response types (Bamashmous et al., 2021).
[0103] Mature plaque in the test site induces changes in the host medium in the control site that precede the shift in the microbiome in the control site
[0104] After determining that both the microbiome and host mediators changed within control sites in inflammatory responder types (IRTs), we sought to investigate whether the temporal relationship between these changes could be resolved between test and control sites in different IRTs. To capture when the greatest shift in host mediators occurred within each IRT control site, we converted our host mediator data during the induction phase (days 0 to 21) into log fold-change (LogFC) values compared to baseline (day 0). We then plotted a z-score heatmap of this LogFC ( Figures 6A to 6C This showed that significant changes occurred within the high-type IRT on day 4 and within the slow-type IRT on day 7, including key pro-inflammatory markers TNF-a, IL-6, and IL-8 ( Figures 6A to 6F ). Notably, this corresponds in time to the shift in the two main gates within the test site in the high-type IRT and the slow-type IRT ( Figures 6G to 6I as well as Figure 4A and 4B ). The temporal relationship between the test site and the control site was less clear in the low-type IRT. Figures 6J to 6K A graphic illustration of the magnitude and timing of these changes in both subgingival community composition and host media in these contralateral test and control sites within the respective IRTs is shown. In summary, the data suggest that systemic effects in the oral cavity have subclinical effects on host media and microbiomes within healthy sites, which may be caused by locally induced inflammation occurring elsewhere in the mouth. As with the microbiomes and host responses of the test sites, this contralateral effect was shown to vary according to the different inflammatory responder types identified by experimental gingivitis.
Claims
1. A method for identifying an individual as a chronic gingivitis responder or a high gingivitis responder, wherein The following steps are involved: a) analyzing the bacterial composition of a subgingival plaque sample of pre-gingivitis origin from said individual to determine a baseline iFBR; b) analyzing the bacterial composition of an early distant healthy source subgingival plaque sample from said individual to determine early iFBR; c) analyzing the bacterial composition of late distant healthy source subgingival plaque samples to determine late iFBR; d) comparing the baseline iFBR, the early iFBR, and the late iFBR, wherein if the early iFBR is not significantly changed compared to the baseline iFBR and the late iFBR is significantly changed compared to the baseline iFBR and the early iFBR, the individual is a slow gingivitis responder, and if the early iFBR is significantly changed compared to the baseline iFBR and the late iFBR is significantly changed compared to the baseline iFBR, the individual is a high gingivitis responder.
2. The method according to claim 1, further comprising: The following steps are involved: i) obtaining a subgingival plaque sample of pre-gingivitis origin from the individual prior to step (a); ii) obtaining an early remote healthy subgingival plaque sample from the individual before step (b); iii) obtaining a late distant healthy-derived subgingival plaque sample from said individual prior to step (c).
3. A method of treating an individual identified as suffering from gingivitis, wherein The following steps are involved: a) identifying the individual as a slow gingivitis responder or a high gingivitis responder by the method of claim 1; b) if the individual is identified as a slow gingivitis responder, applying to the individual's oral cavity one or more oral care compositions comprising one or more ingredients having antimicrobial activity and no additional ingredients having anti-inflammatory activity; if the individual is identified as a high gingivitis responder, applying to the individual's oral cavity one or more oral care compositions comprising one or more ingredients having antimicrobial activity and one or more ingredients having anti-inflammatory activity.
4. The method of claim 3, wherein the one or more ingredients having antimicrobial activity are selected from the group consisting of arginine, zinc phosphate, zinc oxide, zinc citrate, triclosan, digluconate, thymol, menthol, eucalyptol, methyl salicylate, saline, antibiotics, and fluoride.
5. The method of claim 3 or 4, wherein the one or more ingredients having anti-inflammatory activity are selected from the group consisting of chlorhexidine, DHA and vitamin D.
6. The method of any one of claims 3 to 5, wherein the one or more oral care compositions are selected from the group consisting of toothpaste, mouth rinse, and mouthwash.
